Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy. The study met each of the safety and efficacy endpoints, with the optimal treatment regimen achieving a...
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately...